Roy Pettipher
Director of Research
dermatology
ATOLLON
Netherlands
Biography
Roy Pettipher has responsibility for all aspects of inflammation biology and pharmacology for Atopix. He has been Director of Research at Oxagen Ltd for the past 14 years where he initiated the CRTH2 antagonist program. Roy gained 13 years experience in anti-inflammatory drug discovery during his time at Pfizer in the US and, previous to that, at Wellcome in the UK. In the past, Roy has been involved in the initiation and management of a number of drug discovery programmes that have yielded clinical candidates and has published extensively in the field of inflammation biology. His expertise in inflammation biology has proved valuable in the selection and prosecution of CRTH2 as a target for allergic disorders.
Research Interest
